The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Tetsuya Horiuchi - One of the best experts on this subject based on the ideXlab platform.
-
Hyperacute Peripheral Neuropathy is a predictor of oxaliplatin-induced persistent Peripheral Neuropathy
Supportive Care in Cancer, 2017Co-Authors: Hiroyuki Tanishima, Toshiji Tominaga, Masamichi Kimura, Tsunehiro Maeda, Yasutsugu Shirai, Tetsuya HoriuchiAbstract:Purpose Chronic Peripheral Neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute Peripheral Neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent Peripheral Neuropathy (PPN). Methods Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed. HAPN was defined as acute Peripheral Neuropathy (APN) occurring on day 1 (≤24 h after oxaliplatin infusion) of the first cycle. PPN was defined as Neuropathy lasting >1 year after oxaliplatin discontinuation. Results The average total dose of oxaliplatin was 625.8 mg/m^2, and the average relative dose intensity was 66.7%. Twenty-two of the 47 patients (46.8%) had PPN and 13 (27.7%) had HAPN. Male sex, treatment for Neuropathy, HAPN, and APN were significantly more frequent in patients with PPN ( p = 0.013, 0.02,
-
Hyperacute Peripheral Neuropathy is a predictor of oxaliplatin-induced persistent Peripheral Neuropathy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016Co-Authors: Hiroyuki Tanishima, Toshiji Tominaga, Masamichi Kimura, Tsunehiro Maeda, Yasutsugu Shirai, Tetsuya HoriuchiAbstract:Purpose Chronic Peripheral Neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute Peripheral Neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent Peripheral Neuropathy (PPN).
Gini F. Fleming - One of the best experts on this subject based on the ideXlab platform.
-
Chemotherapy-induced Peripheral Neuropathy: Current status and progress.
Gynecologic oncology, 2015Co-Authors: Jamie Renee Brewer, Gladys Morrison, M. Eileen Dolan, Gini F. FlemingAbstract:As there are increasing numbers of cancer survivors, more attention is being paid to the long term unwanted effects patients may experience as a result of their treatment and the impact these side effects can have on their quality of life. Chemotherapy-induced Peripheral Neuropathy (CIPN) is one of the most common long-term toxicities from chemotherapy. In this review we will briefly review the clinical presentation, evaluation and management of chemotherapy-induced Peripheral Neuropathy, with a focus on CIPN related to platinum and taxane agents. We will then discuss current clinical models of Peripheral Neuropathy and ongoing research to better understand CIPN and develop potential treatment options.
A. Gordon Smith - One of the best experts on this subject based on the ideXlab platform.
-
Peripheral Neuropathy Research Registry: A prospective cohort.
Journal of the peripheral nervous system : JPNS, 2019Co-Authors: Simone Thomas, A. Gordon Smith, Roy Freeman, David M. Simpson, Senda Ajroud-driss, Mazen M. Dimachkie, Christopher H. Gibbons, J. Robinson Singleton, Ahmet HokeAbstract:The Peripheral Neuropathy Research Registry (PNRR) is a prospective cohort of Peripheral Neuropathy (PN) patients focused on idiopathic axonal Peripheral Neuropathy. Patients with diabetic, human immunodeficiency virus-, and chemotherapy-induced Peripheral neuropathies are enrolled as comparison groups. The PNRR is a multi-center collaboration initiated and funded by the Foundation for Peripheral Neuropathy (FPN) with the objective to recruit a well characterized cohort of patients with different phenotypes and symptoms in each diagnostic category, and to advance research through development of biomarkers and identification of previously unknown causes of PN. The overall goal of the initiative is to find disease-altering treatments and better symptom relief for patients. We present the study design, types of data collected, and characteristics of the first 1150 patients enrolled. We also discuss ongoing analyses on this dataset, including untargeted-omics methodologies.
-
Peripheral Neuropathy.
The Medical clinics of North America, 2018Co-Authors: Kelsey Barrell, A. Gordon SmithAbstract:Peripheral Neuropathy is a commonly encountered disorder in clinical practice. In light of an aging population and the diabetes and obesity pandemic, the prevalence of Peripheral Neuropathy is increasing, posing a significant public health concern. This article provides a diagnostic framework for neuropathies and summarizes treatment options.
-
Exercise in Type 2 Diabetic Peripheral Neuropathy
Current Geriatrics Reports, 2016Co-Authors: Arwen A. Fuller, A. Gordon Smith, J. Robinson Singleton, Robin L. MarcusAbstract:Approximately half of all patients with type 2 diabetes develop Peripheral Neuropathy, which contributes to functional decline and significantly reduces quality of life. Type 2 diabetes and consequent diabetic Peripheral Neuropathy share several pathogenic mechanisms and are both positively influenced by increased physical activity and exercise even prior to disease diagnosis. Successful exercise interventions in individuals with diabetic Peripheral Neuropathy have employed continuous endurance, resistance, balance and agility, and high-intensity interval training protocols and have been associated with improvement in stability, gait, sensory function, nerve regeneration rates, pain, mood, and quality of life. Recent evidence has shown no increased prevalence of foot trauma in those with diabetic Peripheral Neuropathy suggesting that weight-bearing exercise is safe in the absence of active ulceration. While exercise is often associated with improved glycemic control, several studies suggest improvement in Neuropathy is independent of improved glycemic control or weight reduction, suggesting other metabolic effects, or exercise-related physiologic changes are important.
-
Handbook of Peripheral Neuropathy - Handbook of Peripheral Neuropathy
2005Co-Authors: Mark B. Bromberg, A. Gordon SmithAbstract:Handbook of Peripheral Neuropathy , Handbook of Peripheral Neuropathy , کتابخانه دیجیتال جندی شاپور اهواز
Hiroyuki Tanishima - One of the best experts on this subject based on the ideXlab platform.
-
Hyperacute Peripheral Neuropathy is a predictor of oxaliplatin-induced persistent Peripheral Neuropathy
Supportive Care in Cancer, 2017Co-Authors: Hiroyuki Tanishima, Toshiji Tominaga, Masamichi Kimura, Tsunehiro Maeda, Yasutsugu Shirai, Tetsuya HoriuchiAbstract:Purpose Chronic Peripheral Neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute Peripheral Neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent Peripheral Neuropathy (PPN). Methods Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed. HAPN was defined as acute Peripheral Neuropathy (APN) occurring on day 1 (≤24 h after oxaliplatin infusion) of the first cycle. PPN was defined as Neuropathy lasting >1 year after oxaliplatin discontinuation. Results The average total dose of oxaliplatin was 625.8 mg/m^2, and the average relative dose intensity was 66.7%. Twenty-two of the 47 patients (46.8%) had PPN and 13 (27.7%) had HAPN. Male sex, treatment for Neuropathy, HAPN, and APN were significantly more frequent in patients with PPN ( p = 0.013, 0.02,
-
Hyperacute Peripheral Neuropathy is a predictor of oxaliplatin-induced persistent Peripheral Neuropathy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016Co-Authors: Hiroyuki Tanishima, Toshiji Tominaga, Masamichi Kimura, Tsunehiro Maeda, Yasutsugu Shirai, Tetsuya HoriuchiAbstract:Purpose Chronic Peripheral Neuropathy is a major adverse response to oxaliplatin-containing chemotherapy regimens, but there are no established risk factors pertaining to it. We investigated the efficacy of hyperacute Peripheral Neuropathy (HAPN) as a predictor of oxaliplatin-induced persistent Peripheral Neuropathy (PPN).
Koichi Akashi - One of the best experts on this subject based on the ideXlab platform.
-
Management of Chemotherapy-Induced Peripheral Neuropathy
Annals of Oncology, 2012Co-Authors: Eishi Baba, Hitoshi Kusaba, Shigeo Takaishi, Koichi AkashiAbstract:ABSTRACT Chemotherapy-induced Peripheral Neuropathy often appears in the cancer patients and sometimes limits dose-intensity of the anti-cancer agents. Common symptoms include a Peripheral sensory Neuropathy such as paresthesia and tingling, Peripheral motor Neuropathy such as loss of deep tendon reflexes and distal muscle weakness. Autonomic disturbance including constipation, orthostatic hypotension and urinary retention also appear. Since a diagnostic criterion of drug-induced Peripheral Neuropathy has not been established, its diagnosis often depends on appearance of bilateral symptoms after certain period of the drug exposure, amelioration of symptoms by the drug reduction, and lower action potential in a nerve conduction study. In addition to cytotoxic agents including taxan, platinum and vinca alkaloid, bortezomib and thalidomide are also likely to have Peripheral Neuropathy. Several pathogenic mechanisms of chemotherapy- induced Peripheral Neuropathy have been proposed. Axonopathy is caused by axonal transport inhibition via microtubule disruption by taxan, vinca alkaloid and thalidomide. Bortezomib and platinum cause neuronopathy in association with mitochondria-mediated apoptosis. Inhibition of neurotrophin is thought to be involved in bortezomib-induced neuronopathy. Myelinopathy is caused by interferon alpha, which may enhance auto-reactive T lymphocytes. In order to achieve enough dose-intensity of chemotherapy, prevention and symptom amelioration of chemotherapy-induced Neuropathy are important. Supplement of calcium and magnesium was suggested to be effective for prevention. Vitamin B6 and B12, pregabalin, tricyclic antidepressant and herbal preparation are sometimes employed for amelioration of symptoms. Since discontinuation or reduction of the causative agent is generally required in case of severe chemotherapy-induced Neuropathy, careful consideration should be given individually.
